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Abstract 
The clinical response of high-grade serous ovarian cancer (HGSOC) patients to the standard             
platinum-based chemotherapy varies widely. While all patients ultimately become resistant, a           
wide variation in the delay between successive treatments is observed. In an effort to learn               
more about the molecular basis of resistance, we decided to examine how this variation is               
manifested in tumor gene expression levels. 
The activities of homologous recombination (HR) and Fanconi anemia (FA) pathways are known             
to correlate with resistance. We therefore hypothesized that the expression of the genes in the               
above pathways (HR+FA genes) could be linked to resistance in a predictive model that would               
accurately classify patients into “resistant” or “sensitive” phenotypes. To focus our analysis on             
the signal of cancer-related cells within bulk data, we applied a computational deconvolution             
method, and used the epithelial ovarian cancer component to evaluate our hypothesis.  
In a dataset from the HERCULES consortium, the accuracy of a classifier based on the HR+FA                
genes was 0.79, while it was 0.59 in a TCGA dataset. We explored whether any of the HR+FA                  
genes differed significantly between resistant and sensitive patients in the HERCULES dataset.            
We observed that ABRAXAS1 significantly differed (p<0.05 after Benjamini-Hochberg         
correction, Mann-Whitney U test). Our subsequent accuracy estimate of an ABRAXAS1-only           
classifier was 0.84. We also found a subgroup of HR-related genes (BRCA1, ABRAXAS1,             
FANCC, PMS2, RAD50) that led to an accuracy estimate of 0.96. 
1. Introduction 
In 2019 there will be approximately 22,530 new cases of ovarian cancer diagnosed and 13,980               
ovarian cancer deaths in the United States [1]. Ovarian carcinoma are generally classified as              
Type I or Type II, and different histological subtypes with distinct clinicopathological and             
molecular genetic features [2]. Type II tumors are primarily composed of high-grade serous             
carcinomas. These tumors are characterized by late detection, rapid and aggressive           
progression and poor overall clinical outcome. The standard treatment in high-grade serous            
ovarian cancer (HGSOC) is aggressive surgery followed by platinum–taxane chemotherapy [3]           
Although the patients benefit from chemotherapy initially, chemoresistance almost always          
emerges [2]. 
In this study we aimed to explore the predictability of platinum resistance in high-grade serous               
ovarian cancer (HGSOC) patients using transcriptomic data. Based on the known correlation            
between the activity of the Homologous Recombination (HR) pathway and primary platinum            
sensitivity [4], we hypothesized that HR and Fanconi Anemia (FA) related genes (HR+FA             
genes) could be used to classify new patients as either resistant or sensitive. 
2. Materials & Methods 
2.1 Datasets 
We used HGSOC mRNA expression data obtained from HERCULES consortium and The            
Cancer Genome Atlas consortium [3]. 
HERCULES mRNA expression data came from primary tumors. Patients whose primary therapy            
outcomes were “progressive disease” or “progressive disease after neoadjuvant chemotherapy”          
were labeled as “resistant”. Patients whose primary therapy outcomes were “complete           
response” were labeled as “sensitive”. Samples from ascites, adnex and lymph node were             
removed and samples from fallopian tube, mesenterium, omentum, ovary and peritoneum were            
used, leaving samples from 7 resistant and 17 sensitive patients. For the patients with multiple               
samples, expression values were averaged. 
TCGA patients were labeled as “resistant” if their recorded platinum-free interval was 180 days              
or less, and as “sensitive” otherwise. This led to 35 resistant patients and 101 sensitive patients.                
We used the data from the 35 resistant patients and those 35 sensitive patients with highest                
(>600) platinum free interval days. 
2.2 Processing of bulk mRNA data 
To deal with varying proportions of cancer cells in our samples, we used a deconvolution               
approach to estimate gene expression in epithelial ovarian cancer fraction. We used 16,826             
HERCULES single-cell RNA-seq profiles from 18 biopsies (15 patients) to estimate the cell type              
composition and the constituent expression profiles of each bulk sample. Single cell profiles             
were classified as ovarian cancer, fibroblast, immune, or unknown cell type using clustering and              
marker genes, and then used to decompose the bulk samples in these components. 
The deconvolution method models heterogeneity and adapts to unmatched patients and           
specificities of each bulk sample. This allows the estimation of specific cancer cell expression              
profiles free of compositional variation and variation in the expression profiles of adjacent             
stromal and immune cells. 
After deconvolution, we performed normalization and a variance-stabilizing transformation using          
DESeq2 [5] 
2.3 Classification approach 
We constructed a classifier using the Nearest Centroid Classification method from the            
scikit-learn library [6]. Performance was evaluated by repeating randomized 5-fold          
cross-validation 10 times, leading to average accuracy estimates across 50 runs. 
2.4 Gene selection 
We focused our analysis on the combined set of genes that were annotated as either               
“Homologous Recombination” or “Fanconi Anemia” in Kyoto Encyclopedia of Genes and           
Genomes (KEGG) [7, 8]. 
In order to choose a subgroup from HR+FA genes that will lead to better prediction, we used the                  
following approaches independently: 
Mann-Whitney U test​: We applied Mann-Whitney U test to explore whether any of the HR+FA               
genes differed between resistant and sensitive patients. We used the most strongly differentially             
expressed genes for prediction. The degree of differential expression of a gene was quantified              
by the p-value of the Mann-Whitney U test. 
Sequential feature selection (SFS)​: SFS is a greedy method for feature selection which either              
starts with an empty feature set and iteratively adds those features that provide the highest               
increase in empirical classification performance, until no further increase can be achieved            
(forward selection), or starts with the full feature set and iteratively removes features (backward              
selection). We used Sequential Forward Selection from MLxtend library [9] to get best two              
genes among HR+FA genes for prediction. SFS has been applied on each fold of              
crossvalidation independently. 
SFS merging​: Genes returned by SFS in each fold of crossvalidation were aggregated and              
genes that appeared more than 5 times, out of 50 total runs, were selected for the merged set. 
3. Results 
The balanced accuracy estimates of the nearest centroid classifier, using features obtained by             
different methods, are given in Table 1. 
The accuracy was 0.53 for both HERCULES and TCGA datasets using all genes as features.               
When HR+FA genes were used, the accuracy increased to 0.79 for the HERCULES dataset              
and it increased to 0.59 for the TCGA dataset. 
In the HERCULES dataset, ABRAXAS1 was found to be significantly differentially expressed            
between resistant and sensitive patients within HR+FA genes (p<0.05 after Benjamini-Hochberg           
correction, Mann-Whitney U test). Based on this finding we tested an ABRAXAS1-only classifier             
which gave an accuracy estimate of 0.84. 
In the TCGA data, no gene differed significantly, TOP3B was the most differentially expressed              
gene. The accuracy of a TOP3B-only classifier was 0.63. 
The best accuracy estimate was obtained by using features received from SFS merging. In the               
HERCULES dataset, the gene set ABRAXAS1, FANCC, RAD50, BRCA1, PMS2 resulted in an             
accuracy of 0.96. In Figure 1 and Figure 2 these genes are highlighted. In the TCGA dataset,                 
the gene set TOP3B, SLX1B, HES1, POLK, RAD51B resulted in an accuracy of 0.73.   
Table 1.​ Accuracy estimates obtained from different candidate gene sets 
Method HERCULES 
data 
TCGA data 
Using all genes 0.53 0.53 
HR+FA genes 0.79 0.59 
SFS on HR+FA 0.70 0.54 
SFS merging on HR+FA 0.96 0.73 
10 most strongly differentially 
expressed HR+FA genes 0.90 0.68 
The most strongly differentially 
expressed HR+FA gene 0.84 0.63 
 
4. Conclusions and Future Directions 
In this study we aimed to learn about the molecular basis of platinum-based chemotherapy              
resistance in high-grade serous ovarian cancer patients. As the activities of homologous            
recombination and Fanconi anemia pathways are known to correlate with resistance, we            
hypothesized that the expression of the genes in these pathways could be linked to resistance               
in a predictive model that would accurately classify patients into “resistant” or “sensitive”             
phenotypes. We used datasets from HERCULES and TCGA consortia. In two datasets we             
obtained different predictive gene sets; in the HERCULES dataset the genes were ABRAXAS1,             
FANCC, RAD50, BRCA1, PMS2, which resulted in an accuracy of 0.96, and in the TCGA               
dataset the genes were TOP3B, SLX1B, HES1, POLK, RAD51B, which resulted in an accuracy              
of 0.73. This confirms our hypothesis that Homologous Recombination- and Fanconi           
Anemia-related transcripts can indeed be used for the prediction of platinum resistance. The             
differences between the obtained predictive gene sets and between the accuracy scores            
necessitates further research with other/larger datasets. The obtained gene sets may represent            
starting points for more detailed statistical and experimental evaluation of the role of these              
genes in platinum resistance. 
 
 Figure 1.​ Homologous Recombination pathway. Genes selected by SFS merging (ABRAXAS1, 
RAD50, BRCA1) are highlighted. 
 Figure 2.​ Fanconi Anemia pathway. Genes selected by SFS merging are highlighted. 
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